Viral kinetics and duration of hepatitis C therapy

Sidharth S. Bhardwaj, Paul Y. Kwo

Research output: Contribution to journalArticle

Abstract

Treatment for hepatitis C is aimed at eliminating the virus and thus preventing the development of cirrhosis. The effectiveness of antiviral therapy with pegylated interferon and ribavirin is based upon inhibition of viral replication and successful viral clearance while maintaining minimal toxicity. Therapy as short as 12 to 16 weeks duration may be adequate for those with genotypes 2 or 3, and 24 weeks may be sufficient for those with genotype 1 and low viral load who achieve rapid virologic response. On the other hand, extension of therapy beyond 48 weeks may be necessary for those with genotype 1 and slow response or those with a high pretreatment viral load who do not achieve rapid virologic response. As new viral kinetic data emerge with pegylated interferon and ribavirin, the tailoring of hepatitis C virus treatment will allow shorter durations of therapy for some patients and a greater chance of sustained response in others who are treated for longer durations.

Original languageEnglish
Pages (from-to)68-74
Number of pages7
JournalCurrent Hepatitis Reports
Volume6
Issue number2
StatePublished - May 2007

Fingerprint

Hepatitis C
Ribavirin
Genotype
Viral Load
Interferons
Therapeutics
Hepacivirus
Antiviral Agents
Fibrosis
Viruses

ASJC Scopus subject areas

  • Hepatology
  • Virology

Cite this

Bhardwaj, S. S., & Kwo, P. Y. (2007). Viral kinetics and duration of hepatitis C therapy. Current Hepatitis Reports, 6(2), 68-74.

Viral kinetics and duration of hepatitis C therapy. / Bhardwaj, Sidharth S.; Kwo, Paul Y.

In: Current Hepatitis Reports, Vol. 6, No. 2, 05.2007, p. 68-74.

Research output: Contribution to journalArticle

Bhardwaj, SS & Kwo, PY 2007, 'Viral kinetics and duration of hepatitis C therapy', Current Hepatitis Reports, vol. 6, no. 2, pp. 68-74.
Bhardwaj, Sidharth S. ; Kwo, Paul Y. / Viral kinetics and duration of hepatitis C therapy. In: Current Hepatitis Reports. 2007 ; Vol. 6, No. 2. pp. 68-74.
@article{7615c66946754ff2b5c0249b183450d8,
title = "Viral kinetics and duration of hepatitis C therapy",
abstract = "Treatment for hepatitis C is aimed at eliminating the virus and thus preventing the development of cirrhosis. The effectiveness of antiviral therapy with pegylated interferon and ribavirin is based upon inhibition of viral replication and successful viral clearance while maintaining minimal toxicity. Therapy as short as 12 to 16 weeks duration may be adequate for those with genotypes 2 or 3, and 24 weeks may be sufficient for those with genotype 1 and low viral load who achieve rapid virologic response. On the other hand, extension of therapy beyond 48 weeks may be necessary for those with genotype 1 and slow response or those with a high pretreatment viral load who do not achieve rapid virologic response. As new viral kinetic data emerge with pegylated interferon and ribavirin, the tailoring of hepatitis C virus treatment will allow shorter durations of therapy for some patients and a greater chance of sustained response in others who are treated for longer durations.",
author = "Bhardwaj, {Sidharth S.} and Kwo, {Paul Y.}",
year = "2007",
month = "5",
language = "English",
volume = "6",
pages = "68--74",
journal = "Current Hepatitis Reports",
issn = "1540-3416",
publisher = "Springer Publishing Company",
number = "2",

}

TY - JOUR

T1 - Viral kinetics and duration of hepatitis C therapy

AU - Bhardwaj, Sidharth S.

AU - Kwo, Paul Y.

PY - 2007/5

Y1 - 2007/5

N2 - Treatment for hepatitis C is aimed at eliminating the virus and thus preventing the development of cirrhosis. The effectiveness of antiviral therapy with pegylated interferon and ribavirin is based upon inhibition of viral replication and successful viral clearance while maintaining minimal toxicity. Therapy as short as 12 to 16 weeks duration may be adequate for those with genotypes 2 or 3, and 24 weeks may be sufficient for those with genotype 1 and low viral load who achieve rapid virologic response. On the other hand, extension of therapy beyond 48 weeks may be necessary for those with genotype 1 and slow response or those with a high pretreatment viral load who do not achieve rapid virologic response. As new viral kinetic data emerge with pegylated interferon and ribavirin, the tailoring of hepatitis C virus treatment will allow shorter durations of therapy for some patients and a greater chance of sustained response in others who are treated for longer durations.

AB - Treatment for hepatitis C is aimed at eliminating the virus and thus preventing the development of cirrhosis. The effectiveness of antiviral therapy with pegylated interferon and ribavirin is based upon inhibition of viral replication and successful viral clearance while maintaining minimal toxicity. Therapy as short as 12 to 16 weeks duration may be adequate for those with genotypes 2 or 3, and 24 weeks may be sufficient for those with genotype 1 and low viral load who achieve rapid virologic response. On the other hand, extension of therapy beyond 48 weeks may be necessary for those with genotype 1 and slow response or those with a high pretreatment viral load who do not achieve rapid virologic response. As new viral kinetic data emerge with pegylated interferon and ribavirin, the tailoring of hepatitis C virus treatment will allow shorter durations of therapy for some patients and a greater chance of sustained response in others who are treated for longer durations.

UR - http://www.scopus.com/inward/record.url?scp=34249891659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249891659&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:34249891659

VL - 6

SP - 68

EP - 74

JO - Current Hepatitis Reports

JF - Current Hepatitis Reports

SN - 1540-3416

IS - 2

ER -